Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced cost-cutting plan ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...

Outside of the core registrational programs for these two important indications, we have several additional ongoing phase ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its ...